Stocktoria
Spero Therapeutics, Inc. SPRO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-11-02
Spero Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 9.5% | -152.9% | 20.7% | -78.9% | -481.9% |
| Net margin | 12.8% | -142.9% | 22.0% | — | -491.9% |
| Return on assets | 12.4% | -62.0% | 12.5% | — | -52.5% |
| Return on equity | 14.5% | -148.7% | 21.3% | — | -101.7% |
| Current ratio | 7.59 | 2.19 | 3.53 | 5.25 | 8.46 |
| Revenue growth | 39.2% | -53.8% | 94.0% | 193.1% | 95.7% |
Source: SEC EDGAR filings · CIK 0001701108 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.